As a full-service cell and gene biosafety partner, GeneWerk provides clarity on the safety of the therapies in development very early on in the process.
Our GCLP-compliant services – from sample preparation to report delivery – are designed to help you to meet pre-clinical safety standards for emerging gene therapies.Get in touch
Our comprehensive services for pre-clinical safety assessment include integration site analysis, vector persistence testing, clonal expansion, vector integration profiling, gene editing on-/off-target analysis, vector copy number (VCN), vector quality control, and immune repertoire analysis.
These services combined with our dedicated bioinformatics pipelines enable precise decision-making to successfully navigate the regulatory landscape.
Read our latest press releases and announcements below.
GeneWerk will expand capabilities to meet rapidly growing demand for cell and gene therapy...